Chief Business Officer · Dianthus Therapeutics, Inc. (DNTH)

Christina Isacson

FY2018 is the first fiscal year CompBrief holds for Christina Isacson as a named executive officer of Dianthus Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$2,277,560

Salary $322,510Stock awards $0

3rd of 3 named executive officers at Dianthus Therapeutics by FY2018 total.

3 named officers on file for Dianthus Therapeutics, FY2018

Christina Isacson’s pay file — $29

  • 1 fiscal year of pay, line by line
  • DNTH’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Dianthus Therapeutics’s whole pay program stands against its peers

  • Dianthus Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DNTH→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2019 (DEF 14A).

Free

Get Christina Isacson’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Christina Isacson compensation by year

Dianthus Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Dianthus Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018
Salary$322,510
Bonus$0
Stock awards$0
Option awards$1,821,050
Non-equity incentive$134,000
Pension and deferred compensation$0
All other$0
Total$2,277,560

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Dianthus Therapeutics, Inc. DEF 14A filed April 25, 2019, accession 0001193125-19-119735, and prior-year filings.

How this page was built: the Dianthus Therapeutics, Inc. filed document, accession 0001193125-19-119735. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2019.

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU29,994$170,966—
Option105,747—$7.71
Option147,105—$9.49

Per the Outstanding Equity Awards at Fiscal Year-End table in Dianthus Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Dianthus Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
D.Phil. Jason GardnerPresident and Chief Executive Officer$4,749,458
John DavisChief Medical Officer$3,175,746
Christina Isacson · this pageChief Business Officer$2,277,560

The full Dianthus Therapeutics compensation record

free company brief

This page is one person within Dianthus Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Dianthus Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Dianthus Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christina Isacson's compensation dossier · One-time report. No refunds.